• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Profusa Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    3/12/26 9:29:39 PM ET
    $PFSA
    Medical/Dental Instruments
    Health Care
    Get the next $PFSA alert in real time by email
    false 0001859807 0001859807 2026-03-11 2026-03-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): March 11, 2026

     

    PROFUSA, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41177   86-3437271
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    626 Bancroft Way, Suite A

    Berkeley, CA 94710

    (Address of principal executive offices, including zip code)

     

    Registrant’s telephone number, including area code: (925) 997-6925

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   PFSA   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.02. Termination of a Material Definitive Agreement.

     

    On March 12, 2026, Ascent Partners Fund LLC (the “Secured Party”) notified the Company of the termination of the Account Control Agreement (the “Control Agreement”), dated as of September 29, 2025, among the Company, as pledgor, the Secured Party, BitGo Prime LLC (the “Delegate”), and BitGo Trust Company, Inc. (the “Custodian”). The termination was made pursuant to Section 9(c) of the Control Agreement and will be effective 30 days after the filing of this Current Report on Form 8-K.

     

    The Control Agreement was entered into in connection with the closing of the second tranche of the Company’s financing arrangement with the Secured Party pursuant to that certain Securities Purchase Agreement, dated as of February 11, 2025 (as amended, the “Securities Purchase Agreement”). Under the Control Agreement, the Custodian held and managed the Company’s Bitcoin holdings as digital asset collateral in a designated custodial account for the benefit of the Secured Party. The Control Agreement set forth the procedures for the Custodian to follow with respect to entitlement orders and instructions regarding the collateral, including joint control provisions prior to an event of default.

     

    The termination of the Control Agreement was made in connection with the Company’s decision to terminate its Bitcoin treasury reserve strategy and liquidate its Bitcoin holdings, as described below under Item 2.01. No early termination penalties were incurred by the Company in connection with the termination of the Control Agreement.

     

    Item 2.01. Completion of Acquisition or Disposition of Assets.

     

    On March 11, 2026, the Company’s management made the determination to terminate the Company’s Bitcoin treasury reserve strategy in light of current market conditions and the Company’s evaluation of its capital allocation priorities. As previously disclosed, the Company had implemented the Bitcoin treasury strategy using proceeds from its committed equity facility with Ascent Partners Fund LLC to purchase Bitcoin as part of its ongoing treasury management operations.

     

    As of the date of the Company’s most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, the Company’s Bitcoin treasury holding totaled approximately 16.51 Bitcoin, acquired at an aggregate cost of approximately $2.0 million.

     

    The Company will complete the liquidation of its entire Bitcoin treasury holdings over the next few days. The Company plans to sell its remaining Bitcoin through open market transactions to unrelated purchasers. The proceeds from the sale of the Company’s Bitcoin holdings will be used for general corporate purposes.

     

    1

     

     

    Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    As previously disclosed, on September 11, 2025, the Company received a notice (the “MVLS Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon its review of the market value of listed securities (“MVLS”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), from July 29, 2025 to September 10, 2025, the Company no longer met Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Rule”), which requires companies listed on the Nasdaq Global Market to maintain a minimum MVLS of $50,000,000. The Company was initially provided 180 calendar days, or until March 10, 2026, to regain compliance with the MVLS Rule. The Company was unable to regain compliance with the MVLS Rule by March 10, 2026.

       

    Also, as previously disclosed, on September 11, 2025, the Company received a second notice (the “Bid Price Notice”) from Nasdaq notifying the Company that, based upon its review of the closing bid price of the Common Stock, from July 29, 2025 to September 10, 2025, the Company no longer met Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”), which requires companies listed on the Nasdaq Global Market to maintain a minimum bid price of $1.00 per share. The Company was initially provided 180 calendar days, or until March 10, 2026, to regain compliance with the Minimum Bid Price Rule. The Company was unable to regain compliance with the Minimum Bid Price Rule by March 10, 2026

     

    On March 11, 2026, the Company received a letter from the Listing Qualifications Department of Nasdaq notifying the Company that it has not regained compliance with the MVLS Rule and is now subject to delisting from the Nasdaq Global Market. In the same letter, Nasdaq also notified the Company that it has not regained compliance with the Minimum Bid Price Rule and is now subject to delisting from the Nasdaq Global Market on this additional basis.

     

    The Company may appeal Nasdaq’s determination to a Hearings Panel, pursuant to the procedures set forth in the Nasdaq Listing Rules 5800 Series. A hearing request will stay the suspension of the Company’s securities pending the Hearing Panel’s decision. In the hearing, the Company will be asked to provide a plan to regain compliance to the Hearing Panel. The Company has until March 20, 2026 to request an appeal of the determination. If it does not request an appeal by such date, the Company’s Common Stock will be scheduled for delisting at the opening of business on March 20, 2026. The Company intends to timely request a hearing before the Panel to request additional time to regain compliance with the MVLS Rule and Minimum Bid Price Rule. If timely filed, the hearing request will result in a stay of any suspension or delisting action pending the hearing.

     

    Item 9.01. Financial Statements and Exhibits.

     

    Exhibit   Description
    10.1   Termination of Account Control Agreement, dated March 12, 2026, from Ascent Partners Fund LLC to BitGo Trust Company, Inc.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    March 12, 2026 Profusa, Inc.
         
      By: /s/ Ben Hwang
      Name: Ben Hwang
      Title: Chief Executive Officer

     

    3

    Get the next $PFSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PFSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PFSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Knechtel Fred S. acquired 818,961 shares (SEC Form 4)

    4 - Profusa, Inc. (0001859807) (Issuer)

    2/2/26 6:40:58 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    Large owner Northview Sponsor I, Llc disposed of 4,743,750 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Profusa, Inc. (0001859807) (Issuer)

    2/2/26 6:36:30 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    Director O'Rourke Peter acquired 107,750 shares (SEC Form 4)

    4 - Profusa, Inc. (0001859807) (Issuer)

    1/30/26 9:50:38 PM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    $PFSA
    SEC Filings

    View All

    Profusa Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - Profusa, Inc. (0001859807) (Filer)

    3/12/26 9:29:39 PM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Profusa Inc.

    EFFECT - Profusa, Inc. (0001859807) (Filer)

    3/4/26 12:15:14 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    SEC Form POS AM filed by Profusa Inc.

    POS AM - Profusa, Inc. (0001859807) (Filer)

    3/2/26 9:10:43 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    $PFSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering

    After Reevaluating its Near-term Capital Needs Given the Recent Changes in its Projected 2026 Revenue and Mayo Collaboration, the Company Determined that a $15 Million Offering is Not Required to Achieve Near-term Revenue Projections BERKELEY, CA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces it has elected not to proceed with its public offering and intends to file a post-effective amendment with the U.S. Securities and Exchange Commission (the "SEC") for the Company's

    2/27/26 9:15:00 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance

    With strong underlying market demand, European distributor and expert physician customer purchase orders are being received by the Company as its 2026 revenue guidance range increases to $1.5 million - $3 million BERKELEY, Calif, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces it has received several purchase orders for the Lumee™ tissue oxygen monitoring system from its growing network of European distributors and expert physician customers.  With strong underlying market

    2/19/26 8:30:00 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies

    Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product Seeking to develop and commercialize new tethered continuous oxygen monitoring products for high impact clinical applications BERKELEY, Calif, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform seeking to enable the continuous monitoring of an individual's biochemistry, has entered into a know-how agreement with Mayo Clinic.  The collaboration entails investigation of high impact clinical applicatio

    2/12/26 4:30:00 PM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    $PFSA
    Financials

    Live finance-specific insights

    View All

    Profusa Announces Third Quarter Business and Financial Highlights

    Recapitalization reduced net debt to $14 million as of October 31; achieved key milestones to deliver potential 2026 revenue target BERKELEY, Calif, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces financial results for the third quarter ended September 30, 2025, and provides business highlights. Ben Hwang, Ph.D., Profusa's Chairman and CEO, said, "It was an extremely busy four months for the team, and we are proud of our achievements in such a short period of time. In the third

    11/19/25 5:44:52 PM ET
    $PFSA
    Medical/Dental Instruments
    Health Care

    Report Highlights Growth in AI Biomarker Monitoring as Industry Giant's GPUs Power Next-Gen Platform

    MarketNewsUpdates News Commentary NEW YORK, Sept. 11, 2025 /PRNewswire/ -- The global Diagnostic Biomarker market is experiencing unprecedented growth and is projected to continue to see substantial growth in years to come. A recent report from the (NIH) National Library of Medicine discussed the AI-Assisted Biomarker, said that: "Recently, advancements in healthcare digitization and personalized treatments have led to groundbreaking developments. Utilization of AI and ML has the potential to enhance comprehension of disease onset and progression, potentially uncovering new disease subtypes, unveiling novel drug targets, advancing the field of precision medicine, propelling efforts towards d

    9/11/25 8:45:00 AM ET
    $APLD
    $NBIS
    $NVDA
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology

    $PFSA
    Leadership Updates

    Live Leadership Updates

    View All

    Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O'Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO

    Board addition served in the Trump Administration, overseeing 1,300 facilities serving more than 9 million veterans; New CFO has led finance and operations at companies including Northrop Grumman, Stanley Black & Decker, and DuPont Berkeley, Calif, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces two major leadership additions as of the close of the business combination with NorthView Acquisition Corp (NVAC).  Peter O'Rourke, former Acting U.S. Secretary of Veterans Affair

    8/19/25 8:15:00 AM ET
    $PFSA
    Medical/Dental Instruments
    Health Care